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Antibiotic concentrations vary dramatically in the body and the environment.
Hence, understanding the dynamics of resistance evolution along antibiotic
concentration gradients is critical for predicting and slowing the emergence
and spread of resistance. While it has been shown that increasing the concen-
tration of an antibiotic slows resistance evolution, how adaptation to one
antibiotic concentration correlates with fitness at other points along the gradi-
ent has not received much attention. Here, we selected populations of
Escherichia coli at several points along a concentration gradient for three differ-
ent antibiotics, asking how rapidly resistance evolved and whether populations
became specialized to the antibiotic concentration they were selected on. Popu-
lations selected at higher concentrations evolved resistance more slowly but
exhibited equal or higher fitness across the whole gradient. Populations
selected at lower concentrations evolved resistance rapidly, but overall fitness
in the presence of antibiotics was lower. However, these populations readily
adapted to higher concentrations upon subsequent selection. Our results indi-
cate that resistance management strategies must account not only for the rates
of resistance evolution but also for the fitness of evolved strains.1. Introduction
The extensive use of antibiotics in medicine and agriculture selects for resist-
ance with detrimental consequences for human health [1]. Furthermore, the
rapid evolution of resistance threatens to outpace the discovery of new com-
pounds [2]. To slow the emergence and spread of resistant strains, we need
to understand the factors that influence the evolution and maintenance of
resistance.
Bacteria may be exposed to widely varying doses of antibiotics. During
the course of treatment, antibiotic concentrations are generally high, but
vary temporally and spatially across body tissues and organs, exposing bac-
teria to a variety of selection regimes [3,4]. In the wider environment,
bacteria may be exposed to trace concentrations of antibiotics in sewage,
rivers and soil [5,6]. Importantly, even these extremely low concentrations
of antibiotics can select for resistance mutations [7–9]. Given this heterogen-
eity in selective pressures, it is important to understand whether (i) different
antibiotic concentrations select for different genotypes and (ii) mutations




































1 Previous studies have demonstrated indirectly that selection
at different antibiotic concentrations results in selection for
different genotypes [11–15], but direct examinations of how
adaptation to one antibiotic concentration correlates with fitness
in other environments along an antibiotic concentration gradi-
ent have been, with a few exceptions [16,17], generally absent.
It is conceivable that the fitness rank of genotypes changes
along the antibiotic gradient. For example, it is commonly
assumed that adaptation to higher antibiotic concentrations
incurs a high fitness cost, meaning that these genotypes are
not well adapted at lower concentrations or in the absence of
antibiotics [18–20]. However, it is also possible that populations
selected at one concentration exhibit the highest fitness across
the entire gradient. Which resistant genotype establishes in a
bacterial population at a given antibiotic concentration will
thus depend on interactions between mutation supply rate
and fitness across the concentration gradient. From a resistance
management perspective, poor understanding of the relative fit-
ness of resistant strains across the antibiotic dose gradient limits
our potential to understand how low concentrations of anti-
biotics in the environment might select for resistance at
clinically relevant doses and prevents evaluation of dose
manipulation [21] as a strategy to thwart resistance evolution.
Here, we ask whether: (i) antibiotic concentration impacts
the dynamics of resistance evolution, (ii) populations specialize
to the concentration they were selected in, (iii) resistance is
associated with a fitness cost, and (iv) selection at lower anti-
biotic concentrations constrains subsequent adaptation to
higher concentrations. To address these questions, we evolved
six replicate bacterial populations for 28 days (approximately
200 generations) in one of three antibiotic concentrations (the
concentration at which growth is half of the growth in the
absence of antibiotics—EC50; the minimum inhibitory con-
centration—MIC; and double the MIC—2MIC) (electronic
supplementary material, figure S1) and subsequently measured
the growth of evolved populations in all three antibiotic concen-
trations and in the antibiotic-free environment. We employed
the same experimental design for three antibiotics (tetracycline,
streptomycin and nitrofurantoin) and found that populations
selected at higher concentrations exhibit equal or higher fitness
across all antibiotic concentrations.2. Material and methods
We only give a brief summary here. Details can be found in
electronic supplementary material, S1.
(a) Evolution experiment
In this study, we exposed Escherichia coli K-12 strain to three
antibiotics—tetracycline, streptomycin and nitrofurantoin. These
antibiotics were chosen because they have a different mode of
action and because resistance to them is commonly observed in
experimental evolution studies of resistance, as well as clinical and
agricultural isolates of E. coli [22]. We evolved six replicate popu-
lations at three concentrations of each antibiotic (EC50, MIC and
2MIC), giving rise to 54 evolving populations, and a ‘wild-type’
population, propagated in the absence of antibiotics. EC50 is the
half-maximal effective dose of a given antibiotic, i.e. the concen-
tration of an antibiotic that results in half the OD600 reached by
wild-type cells grown for 24 h in the absence of antibiotics. The
MIC is the lowest antibiotic concentration that resulted in nomeasur-
able growth after 24 h; 2MIC is double the MIC. We obtained these
concentrations by measuring a dose–response of the naivepopulation by transferring 1.5 µl of overnight culture to a serial
dilution of each antibiotic, and measuring OD600 after 24 h of
growth (EC50, MIC and 2MIC, respectively, for: tetracycline—0.44,
1.25 and 2.5 µg ml−1; streptomycin—14.31, 25 and 50 µg ml−1;
nitrofurantoin—7.75, 12.5 and 25 µg ml−1) (electronic supplemen-
tary material, figure S1). During the selection procedure, every
24 h 1.5 µl was transferred to 1.2 ml of fresh medium with the
same antibiotic concentration. Since populations evolving at MIC
and 2MIC could not grow initially, we immigrated 1.5 µl from the
wild-type culture to these populations at every transfer. We immi-
grated half as much to the populations evolving at EC50. After 28
days, we grew all populations in the absence of antibiotics for 24 h,
so that all populations reached a similar density. Then, we trans-
ferred 1.5 µl of each culture into appropriate media, in order to
measure the growth curves of thewild-type and of all evolvedpopu-
lations in (i) the absence of antibiotics and (ii) EC50,MIC and2MICof
the antibiotic in which the populations evolved (three replicate
measurements per population, with each set of replicates performed
simultaneously), using a BioTekH1 plate reader. From these growth
curves, we determined the maximum growth rate, as the greatest
slope of the log-transformed growth curve. In addition, we
measured the dose–response curves of all evolved populations in
the manner described above.
(b) Statistical analyses
We performed a survival analysis (using the survreg function in R)
to determine the effect of the antibiotic concentration on the time to
evolve resistance (for this, we called a population ‘resistant’ when
after a growth cycle (24 h), it reached an OD600 value that was
higher by 0.3 than that reached by the wild-type population). We
tested whether overall differences in maximum growth rates
depended on the selective environment by performing an analysis
of variance (anova(lm) function in R) within each tested environ-
ment (absence of antibiotics, EC50, MIC and 2MIC). To
specifically test for differences between every pairwise combination
of tested concentration within each antibiotic, we followed up
ANOVAwith Holm’s corrected pairwise t-tests. Permutation tests
for the maximum growth rates confirmed the conclusions (elec-
tronic supplementary material, S2). We performed one-sample t-
tests (comparing with the wild-type population) in order to deter-
mine whether resistance was associated with a cost. For further
details, see electronic supplementary material, S1 and S2.
(c) Further selection at 2MIC
We selected populations that originally evolved at EC50 and 2MIC
for another nine transfer cycles at 2MIC, using the same protocol
as above except without the immigration from the wild-type. We
subsequently measured their growth curves at 2MIC and com-
pared the maximum growth rates between them, in the same
manner as described above. Furthermore, we tested whether
differences in maximum growth rates between populations orig-
inally selected at EC50 and at 2MIC changed significantly upon
further selection. To do so, we randomly paired populations
selected at EC50 and 2MIC and calculated differences in maximum
growth rates for both the original evolved populations and those
that had undergone further selection. We performed pairwise
t-tests for all possible pairings and report average p-values.
3. Results
(a) Resistant strains emerge faster at lower
concentrations
Weobserved the evolutionof resistance in all populations by the
end of the selection procedure. We found an effect of antibiotic
concentration on rates of resistance evolution in all three anti-











































































Figure 1. Dynamics of resistance evolution. Kaplan–Meier plots showing the
change in the number of susceptible (non-resistant) populations over the
course of selection, for populations selected at each of three concentrations
(EC50—green, MIC—yellow or 2MIC—red) of (a) tetracycline, (b) strepto-
































1 0.0001; streptomycin: χ2 = 10.9, p < 0.005; nitrofurantoin:
χ2 = 44.3, p < 0.0001). In tetracycline and nitrofurantoin, resist-
ance emerged more slowly in populations selected at high
concentrations. In streptomycin, resistance evolved most
slowly at 2MIC but evolution was faster at MIC than at EC50.
(b) Populations selected at lower concentrations have
lower fitness
We obtained full growth curves of all evolved populations in
EC50, MIC and 2MIC of the antibiotic they were selected in, as
well as in the absenceof antibiotics (figure 2).Weestimated fitness
as the maximum growth rate in the exponential phase obtained
from the growth curves.We also determined three additional fea-
tures of growth curves—the ‘pseudo lag phase’ duration, the
maximum optical density reached and the area under the
curve—but avoid drawing conclusions from them due to the dif-
ficulty of relating these measures to bacterial fitness (see section
‘Growth Assays’ in electronic supplementary material, S1).
In general, we found that populations selected at higher con-
centrations had the same or higher fitness across the whole
concentration gradient (figure 2; for statistical analyses see
electronic supplementary material, S2). Populations selected
below MIC still exhibited growth at higher concentrations,albeit of lower overall fitness than the populations selected at
higher concentrations. The other three measures of fitness pro-
vided further support for this observation (electronic
supplementary material, figures S2–S4; S2), which was also evi-
dent in the dose–response curves of selected populations
(electronic supplementary material, figure S5).
(c) Fitness costs did not depend on the selective
antibiotic concentration
In order to analyse if resistance was associated with a fitness
cost, we compared maximum growth rates in the absence of
antibiotics between the wild-type population (that had
evolved in the absence of antibiotics) and the evolved popu-
lations (figure 2). We found no fitness costs in any of the
populations selected in tetracycline or nitrofurantoin, while
the populations selected in streptomycin exhibited fitness
costs (comparing wild-type to populations selected in EC50:
t5 =−8.37, p < 0.0005; MIC: t5 =−9.17, p < 0.0005; 2MIC:
t5 =−12.00, p < 0.0001).
(d) Further selection at high concentrations leads
to assimilation in fitness
Further selection at high concentrations significantly changes fit-
ness differences. Did selection at lower concentrations not only
select for lower resistance, but also constrain adaptation to
higher antibiotic concentrations? To address this question, we
exposed the populations evolved at EC50 and 2MIC for nine
additional daily transfer cycles (approximately 100 generations)
to high concentrations (2MIC) of the same antibiotic they were
selected in, and asked if fitness differences reduced. After this
further period of evolution, the differences in growth rates
between populations originally selected at EC50 and at 2MIC
had decreased significantly for tetracycline and streptomycin
(electronic supplementary material, figure S6; tetracycline:
p  0.008, streptomycin: p  0.026). A caveat of this analysis is
that the growth rates of the original populations and those that
had undergone further selection were measured on different
days, and growth rates were generally larger for the former
than for the latter. Performing the analysis on growth rates
scaled with the mean growth rate of populations selected at
2MIC led to similar results (tetracycline: p  0.020, streptomycin:
p  0.025, nitrofurantoin: p  0.061). For all antibiotics, differ-
ences in growth rates were insignificant following the period
of additional selection (although differences remain significant
for tetracycline, if the size of the sliding window is reduced
from7 to 6points: t5 =−1.92, p  0.042). Similarly, thedifferences
in other measures of fitness changed (electronic supplementary
material, figures S7–S9; S2.5). Interestingly, two populations that
had originally been selected at EC50 in streptomycin and that
were not able to measurably grow at 2MIC were able to adapt
during this phase of selection despite their poor starting per-
formance. These results indicate that selection by sub-lethal
antibiotic concentrations poses an inherent risk, as rapidly emer-
ging resistance can bedifficult to control by subsequent increases
of antibiotic concentrations.4. Discussion
Bacterial populations selected at higher antibiotic concen-
trations were at least as fit or fitter across the entire gradient
royalsocietypublishing.org/journal/rsbl
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Figure 2. Growth curves and growth rates across antibiotic gradients. Growth curves of evolved populations measured in the absence of antibiotics (no AB), at EC50,
MIC and 2MIC of the antibiotic; they were selected in (a) tetracycline, (b) streptomycin or (c) nitrofurantoin. Darker dots are the mean OD600 across all six populations
selected at the same concentration. Each evolved population was measured in three replicates, and the lighter dots show the mean of those three replicates for each
evolved population. OD600 measurement was taken every 20 min during a 24 h growth cycle. Mean maximum growth rates, as the average over the six populations
selected at the same concentration, are shown for each environment. Error bars denote standard errors of the mean, and asterisks mark environments with significant
differences between growth rates (based on ANOVA tests). Three replicate measurements of the wild-type population were made. Colours indicate the original con-
































1 compared with populations that were exposed to lower anti-
biotic concentrations (figure 2). This means that, while
resistance emerges more slowly at higher antibioticconcentrations (figure 1) [23,24], the populations selected
under those conditions typically exhibited higher fitness.



































1 populations selected below MIC were able to grow at and
above MIC, and rapidly became similar in fitness to popu-
lations selected at high concentrations when further selected
at higher concentrations.
These observations raise a question—why were the geno-
types (mutations) that were selected at higher concentrations
not apparently also selected at lower concentrations? Such evol-
utionary dynamics could result from the distribution of
mutational effects (DME). Many experimental estimates of
DMEs show that small-effect mutations are more abundant
than mutations of large effect [25–29]. It seems plausible that
mutations that provide resistance to high levels of antibiotics
appear at a lower frequency than the mutations that provide a
sufficient benefit only to survive low antibiotic concentrations
[17,30]. Thus, at low concentrations, ‘low-resistance’ mutations
may arise and become abundant before a rare ‘high-resistance’
mutation is even generated. Once low-resistance mutations
have reached high frequency, the fixation of high-resistance
mutations is less likely since it needs to compete with a
well-adapted genotype. At higher concentrations, those low-
resistance mutations confer a smaller fitness benefit, resulting
in them being less frequent or absent. Under such conditions,
when the competition from low-resistance mutations is
reduced, high-resistance mutations that are less frequent can
take over the population.
Two recent studies by Harmand et al. explored the question
of how antibiotic concentration influences resistance evolution,
albeit by adopting different approaches [16,17]. In the first
study, Harmand et al [17] characterized resistance mutations
obtained through fluctuationassays alongan antibiotic gradient,
finding that resistance mutations screened at high concen-
trations have the highest fitness across all concentrations. In
the second study, they used these already resistant strains to
further select for resistance along an antibiotic gradient [16].
There are several critical differences between these and our
study: (i) Harmand et al. selected for resistance only above
MIC, while we also selected below MIC, allowing for de novo
evolution of resistance; (ii) our study falls in between the two
studies since it encompasses the entire evolutionary process
(appearance of first mutations and subsequent adaptation).
The set-up considered in our study corresponds to adaptation
to a sink environment with immigration from an antibiotic-
free reservoir as may happen during antibiotic treatment with
imperfect drug penetration. In contrast with Harmand et al.
[16], who identified that continued exposure to higher concen-
trations of antibiotics led to dose specialization, we found that
generalists emerged readily at higher concentrations and had
higher fitness across the entire gradient (figure 2). Together,
these studies indicate that the effect of the first mutation step is
dominant (at least at the time scales considered in our study)
and point to the complex interplay between antibiotic concen-
tration and evolutionary outcomes.While resistance to many antibiotics in E. coli emerges
through point and other chromosomal mutations [31], this is
not the only means of acquiring resistance. Resistance is often
inherited through horizontal gene transfer, as commonly
observed for tetracycline resistance [32]. Furthermore, resistance
can arise througha rangeofdifferentmechanisms, such asmodi-
fication of the drug target or drug metabolism [33]. Finally,
which mechanisms fix in the population also depends on the
specific strain under selection [34]. All these factors can alter
the course of resistance evolution by, for example, imposing
different costs and using different pathways to compensate for
those costs [35,36]. In this study, we did not characterize the
mechanisms of resistance that underpin the reported
adaptations, andweonly considered evolution through chromo-
somal mutations in one strain of E. coli. More complete
understanding of how antibiotic concentration impacts resist-
ance evolution must further expand on our work to account
for the similarities and differences between variousmechanisms
of resistance and means of their inheritance.
Manipulations of antibiotic concentrations, as well as pesti-
cides and other xenobiotics, form an important resistance
management strategy [21,37–41]. So far, the primary focus has
been on rates of resistance evolution, where the traditional
approach is to use high concentrations [42,43], although this
view has been challengedmore recently [39,41,44]. Considering
the fitness of the evolved strains adds another dimension to the
problem of optimal antibiotic dosing.We show that selection at
high concentrations results in a dilemma: resistant populations
with higher fitness emerge more slowly but display—at least at
the time scales considered here—higher levels of resistance.
Careful consideration of both rates of resistance emergence
and fitness of resistant strains is necessary when adopting
concentration manipulation as a management strategy.
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